These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

396 related items for PubMed ID: 33516560

  • 1. Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment.
    Fagiolini A, Florea I, Loft H, Christensen MC.
    J Affect Disord; 2021 Mar 15; 283():472-479. PubMed ID: 33516560
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
    Montgomery SA, Nielsen RZ, Poulsen LH, Häggström L.
    Hum Psychopharmacol; 2014 Sep 15; 29(5):470-82. PubMed ID: 25087600
    [Abstract] [Full Text] [Related]

  • 4. Validation of the Oxford Depression Questionnaire: Sensitivity to change, minimal clinically important difference, and response threshold for the assessment of emotional blunting.
    Christensen MC, Fagiolini A, Florea I, Loft H, Cuomo A, Goodwin GM.
    J Affect Disord; 2021 Nov 01; 294():924-931. PubMed ID: 34378539
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The Motivation and Energy Inventory (MEI): Analysis of the clinically relevant response threshold in patients with major depressive disorder and emotional blunting using data from the COMPLETE study.
    Christensen MC, Adair M, Loft H, McIntyre RS.
    J Affect Disord; 2023 Feb 15; 323():547-553. PubMed ID: 36395989
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction.
    Jacobsen PL, Mahableshwarkar AR, Chen Y, Chrones L, Clayton AH.
    J Sex Med; 2015 Oct 15; 12(10):2036-48. PubMed ID: 26331383
    [Abstract] [Full Text] [Related]

  • 10. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms.
    Baldwin DS, Florea I, Jacobsen PL, Zhong W, Nomikos GG.
    J Affect Disord; 2016 Dec 15; 206():140-150. PubMed ID: 27474960
    [Abstract] [Full Text] [Related]

  • 11. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study.
    Wang G, Gislum M, Filippov G, Montgomery S.
    Curr Med Res Opin; 2015 Apr 15; 31(4):785-94. PubMed ID: 25650503
    [Abstract] [Full Text] [Related]

  • 12. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder.
    Jacobsen PL, Mahableshwarkar AR, Serenko M, Chan S, Trivedi MH.
    J Clin Psychiatry; 2015 May 15; 76(5):575-82. PubMed ID: 26035185
    [Abstract] [Full Text] [Related]

  • 13. Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder.
    Inoue T, Sasai K, Kitagawa T, Nishimura A, Inada I.
    Psychiatry Clin Neurosci; 2020 Feb 15; 74(2):140-148. PubMed ID: 31725942
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
    Olié JP, Gourion D, Montagne A, Rostin M, Poirier MF.
    Encephale; 2009 Dec 15; 35(6):595-604. PubMed ID: 20004291
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder.
    Nishimura A, Aritomi Y, Sasai K, Kitagawa T, Mahableshwarkar AR.
    Psychiatry Clin Neurosci; 2018 Feb 15; 72(2):64-72. PubMed ID: 28858412
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.